{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T10:21:15Z","timestamp":1793614875814,"version":"4.5.0"},"reference-count":125,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2020,7,23]],"date-time":"2020-07-23T00:00:00Z","timestamp":1595462400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,7,23]],"date-time":"2020-07-23T00:00:00Z","timestamp":1595462400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"MEXT | Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["KAKENHI #19H03684"],"award-info":[{"award-number":["KAKENHI #19H03684"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["cm0106505h"],"award-info":[{"award-number":["cm0106505h"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["lm0203097h"],"award-info":[{"award-number":["lm0203097h"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2020,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>It has been nearly half a century since angioimmunoblastic T-cell lymphoma (AITL) was characterized in the early 1970\u2019s. Our understanding of the disease has dramatically changed due to multiple discoveries and insights. One of the key features of AITL is aberrant immune activity. Although AITL is now understood to be a neoplastic disease, pathologists appreciated that it was an inflammatory condition. The more we understand AITL at cellular and genetic levels, the more we view it as both a neoplastic and an inflammatory disease. Here, we review recent progress in our understanding of AITL, focusing on as yet unsolved questions.<\/jats:p>","DOI":"10.1038\/s41375-020-0990-y","type":"journal-article","created":{"date-parts":[[2020,7,23]],"date-time":"2020-07-23T10:03:49Z","timestamp":1595498629000},"page":"2592-2606","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":165,"title":["Advances in understanding of angioimmunoblastic T-cell lymphoma"],"prefix":"10.1038","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7803-7338","authenticated-orcid":false,"given":"Shigeru","family":"Chiba","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7310-8045","authenticated-orcid":false,"given":"Mamiko","family":"Sakata-Yanagimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,23]]},"reference":[{"key":"990_CR1","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1182\/blood-2005-03-1083","volume":"106","author":"KL Grogg","year":"2005","unstructured":"Grogg KL, Attygalle AD, Macon WR, Remstein ED, Kurtin PJ, Dogan A. Angioimmunoblastic T-cell lymphoma: a neoplasm of germinal-center T-helper cells? Blood. 2005;106:1501\u20132.","journal-title":"Blood."},{"key":"990_CR2","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1097\/00000478-200604000-00009","volume":"30","author":"J Dupuis","year":"2006","unstructured":"Dupuis J, Boye K, Martin N, Copie-Bergman C, Plonquet A, Fabiani B, et al. Expression of CXCL13 by neoplastic cells in angioimmunoblastic T-cell lymphoma (AITL): a new diagnostic marker providing evidence that AITL derives from follicular helper T cells. Am J Surg Pathol. 2006;30:490\u20134.","journal-title":"Am J Surg Pathol"},{"key":"990_CR3","doi-asserted-by":"publisher","first-page":"4952","DOI":"10.1182\/blood-2006-10-055145","volume":"109","author":"L De Leval","year":"2007","unstructured":"De Leval L, Rickman DS, Thielen C, De Reynies A, Huang YL, Delsol G, et al. The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (TFH) cells. Blood. 2007;109:4952\u201363.","journal-title":"Blood"},{"key":"990_CR4","first-page":"13","volume":"14","author":"T Suchi","year":"1974","unstructured":"Suchi T. Atypical lymph node hyperplasia with fatal outcome\u2014a report on the histopathological, immunological and clinical investigations of the cases. Recent Adv RES Res. 1974;14:13\u201334.","journal-title":"Recent Adv RES Res"},{"key":"990_CR5","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1016\/S0140-6736(74)90553-4","volume":"303","author":"G Frizzera","year":"1974","unstructured":"Frizzera G, Moran EMRH. Angioimmunoblastic lymphoadenopathy with dysproteinemia. Lancet. 1974;303:1070\u20133.","journal-title":"Lancet"},{"key":"990_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1056\/NEJM197501022920101","volume":"292","author":"RJ Lukes","year":"1975","unstructured":"Lukes RJ, Tindle BH. Immunoblastic lymphadenopathy a hyperimmune entity resembling Hodgkin\u2019s disease. N Engl J Med. 1975;292:1\u20138.","journal-title":"N Engl J Med"},{"key":"990_CR7","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1002\/1097-0142(197802)41:2<578::AID-CNCR2820410226>3.0.CO;2-8","volume":"41","author":"BN Nathwani","year":"1978","unstructured":"Nathwani BN, Rappaport H, Moran EM, Pangalis GA, Kim H. Immunoblastic lymphadenopathy. Cancer. 1978;41:578\u2013606.","journal-title":"Cancer"},{"key":"990_CR8","first-page":"347","volume":"9","author":"M Shimoyama","year":"1978","unstructured":"Shimoyama M, Minato K, Saito H, Takenaka T, Watanabe S, Nagatani T, et al. Immunoblastic lymphadenopathy (IBL)-like T-cell lymphoma. Jpn J Clin Oncol. 1978;9:347\u201356.","journal-title":"Jpn J Clin Oncol"},{"key":"990_CR9","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/S0140-6736(88)90367-4","volume":"331","author":"AG Stansfeld","year":"1988","unstructured":"Stansfeld AG, Diebold J, Kapanci Y, Kel\u00e9nyi G, Lennert K, Mioduszewska O, et al. Updated Kiel classification for lymphomas. Lancet. 1988;331:292\u20133.","journal-title":"Lancet"},{"key":"990_CR10","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1136\/jcp.40.9.995","volume":"40","author":"T Suchi","year":"1987","unstructured":"Suchi T, Lennert K, Tu LY, Kikuchi M, Sato E, Stansfeld AG, et al. Histopathology and immunohistochemistry of peripheral T cell lymphomas: a proposal for their classification. J Clin Pathol. 1987;40:995\u20131015.","journal-title":"J Clin Pathol"},{"key":"990_CR11","first-page":"549","volume":"133","author":"AC Feller","year":"1988","unstructured":"Feller AC, Griesser H, Schiller CV, Wacker HH, Dallenbach F, Bartels H, et al. Clonal gene rearrangement patterns correlate with immunophenotype and clinical parameters in patients with angioimmunoblastic lymphadenopathy. Am J Pathol. 1988;133:549\u201356.","journal-title":"Am J Pathol"},{"key":"990_CR12","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1182\/blood.V84.5.1361.1361","volume":"84","author":"NL Harris","year":"1994","unstructured":"Harris NL, Jaffe ES, Stein H, Banks PM, Chan JKC, Cleary ML, et al. A revised European-American classification of lymphoid neoplasms. Blood. 1994;84:1361\u201392.","journal-title":"Blood"},{"key":"990_CR13","unstructured":"Jaffe ES, Ralfkiaer E. Angioimmunoblastic T-cell lymphoma. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, editors. Pathology and genetics of tumours of haematoloietic and lymphoid tissues. WHO classification of tumours. 3rd ed. Lyon: IARC Press; 2001."},{"key":"990_CR14","unstructured":"Dogan A, Gaulard P, Jaffe ES, Ralfkiaer E, Muller-Hermelink HK. Angioimmunoblastic T-cell lymphoma. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. editors. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: IARC Press; 2008."},{"key":"990_CR15","unstructured":"Dogan A, Gaulard P, Jaffe ES, Muller-Hermelink HK, de Leval L. Angioimmunoblastic T-cell lymphoma and other nodal lymphomas of T follicular helper cell origin. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Revised 4th ed. Lyon: IARC Press; 2017."},{"key":"990_CR16","unstructured":"Nathwani BN, Jaffe ES. Angioimmunoblastic lymphadenopathy (AILD) and AILD-like T-cell lymphomas. In: Jaffe ES, editor. Surgical pathology of the lymph nodes and related organs. Philadelphila: Saunders; 1995. pp 390\u2013412."},{"key":"990_CR17","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1182\/blood.V99.2.627","volume":"99","author":"A Attygalle","year":"2002","unstructured":"Attygalle A, Al-Jehani R, Diss TC, Munson P, Liu H, Du MQ, et al. Neoplastic T cells in angioimmunoblastic T-cell lymphoma express CD10. Blood. 2002;99:627\u201333.","journal-title":"Blood"},{"key":"990_CR18","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1038\/nri1714","volume":"5","author":"CG Vinuesa","year":"2005","unstructured":"Vinuesa CG, Tangye SG, Moser B, Mackay CR. Follicular B helper T cells in antibody responses and autoimmunity. Nat Rev Immunol. 2005;5:853\u201365.","journal-title":"Nat Rev Immunol"},{"key":"990_CR19","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1016\/j.immuni.2019.04.011","volume":"50","author":"S Crotty","year":"2019","unstructured":"Crotty S. T follicular helper cell biology: a decade of discovery and diseases. Immunity. 2019;50:1132\u201348.","journal-title":"Immunity"},{"key":"990_CR20","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.ccr.2011.06.003","volume":"20","author":"C Quivoron","year":"2011","unstructured":"Quivoron C, Couronn\u00e9 L, Della Valle V, Lopez CK, Plo I, Wagner-Ballon O, et al. TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis. Cancer Cell. 2011;20:25\u201338.","journal-title":"Cancer Cell"},{"key":"990_CR21","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1056\/NEJMc1111708","volume":"366","author":"L Couronn\u00e9","year":"2012","unstructured":"Couronn\u00e9 L, Bastard C, Bernard OA. TET2 and DNMT3A mutations in human T-cell lymphoma. N Engl J Med. 2012;366:95\u20136.","journal-title":"N Engl J Med"},{"key":"990_CR22","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1182\/blood-2011-11-391748","volume":"119","author":"RA Cairns","year":"2012","unstructured":"Cairns RA, Iqbal J, Lemonnier F, Kucuk C, De Leval L, Jais JP, et al. IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma. Blood. 2012;119:1901\u20133.","journal-title":"Blood"},{"key":"990_CR23","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1038\/nature09303","volume":"466","author":"S Ito","year":"2010","unstructured":"Ito S, Dalessio AC, Taranova OV, Hong K, Sowers LC, Zhang Y. Role of tet proteins in 5mC to 5hmC conversion, ES-cell self-renewal and inner cell mass specification. Nature. 2010;466:1129\u201333.","journal-title":"Nature"},{"key":"990_CR24","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/S0092-8674(00)81656-6","volume":"99","author":"M Okano","year":"1999","unstructured":"Okano M, Bell DW, Haber DA, Li E. DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell. 1999;99:247\u201357.","journal-title":"Cell"},{"key":"990_CR25","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/j.ccr.2010.11.015","volume":"18","author":"ME Figueroa","year":"2010","unstructured":"Figueroa ME, Abdel-Wahab O, Lu C, Ward PS, Patel J, Shih A, et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell. 2010;18:553\u201367.","journal-title":"Cancer Cell"},{"key":"990_CR26","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1182\/asheducation-2014.1.287","volume":"2014","author":"J Nangalia","year":"2014","unstructured":"Nangalia J, Green TR. The evolving genomic landscape of myeloproliferative neoplasms. Hematology. 2014;2014:287\u201396.","journal-title":"Hematology"},{"key":"990_CR27","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/leu.2013.336","volume":"28","author":"T Haferlach","year":"2014","unstructured":"Haferlach T, Nagata Y, Grossmann V, Okuno Y, Bacher U, Nagae G, et al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia. 2014;28:241\u20137.","journal-title":"Leukemia"},{"key":"990_CR28","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","volume":"374","author":"E Papaemmanuil","year":"2016","unstructured":"Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI, Paschka P, Roberts ND, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016;374:2209\u201321.","journal-title":"N Engl J Med"},{"key":"990_CR29","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1038\/ng.2872","volume":"46","author":"M Sakata-Yanagimoto","year":"2014","unstructured":"Sakata-Yanagimoto M, Enami T, Yoshida K, Shiraishi Y, Ishii R, Miyake Y, et al. Somatic RHOA mutation in angioimmunoblastic T cell lymphoma. Nat Genet. 2014;46:171\u20135.","journal-title":"Nat Genet"},{"key":"990_CR30","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1038\/ng.2873","volume":"46","author":"T Palomero","year":"2014","unstructured":"Palomero T, Couronn\u00e9 L, Khiabanian H, Kim MY, Ambesi-Impiombato A, Perez-Garcia A, et al. Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas. Nat Genet. 2014;46:166\u201370.","journal-title":"Nat Genet"},{"key":"990_CR31","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1182\/blood-2013-10-531509","volume":"123","author":"O Odejide","year":"2014","unstructured":"Odejide O, Weigert O, Lane AA, Toscano D, Lunning MA, Kopp N, et al. A targeted mutational landscape of angioimmunoblastic T-cell lymphoma. Blood. 2014;123:1293\u20136.","journal-title":"Blood"},{"key":"990_CR32","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1182\/blood-2015-05-644591","volume":"126","author":"C Wang","year":"2015","unstructured":"Wang C, McKeithan TW, Gong Q, Zhang W, Bouska A, Rosenwald A, et al. IDH2R172 mutations define a unique subgroup of patients with angioimmunoblastic T-cell lymphoma. Blood. 2015;126:1741\u201352.","journal-title":"Blood"},{"key":"990_CR33","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1182\/blood-2018-09-872549","volume":"133","author":"TB Heavican","year":"2019","unstructured":"Heavican TB, Bouska A, Yu J, Lone W, Amador C, Gong Q, et al. Genetic drivers of oncogenic pathways in molecular subgroups of peripheral T-cell lymphoma. Blood. 2019;133:1664\u201376.","journal-title":"Blood"},{"key":"990_CR34","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1182\/blood-2016-02-698977","volume":"128","author":"D Vallois","year":"2016","unstructured":"Vallois D, Dobay MPD, Morin RD, Lemonnier F, Missiaglia E, Juilland M, et al. Activating mutations in genes related to TCR signaling in angioimmunoblastic and other follicular helper T-cell-derived lymphomas. Blood. 2016;128:1490\u2013502.","journal-title":"Blood"},{"key":"990_CR35","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1038\/ng.2916","volume":"46","author":"HY Yoo","year":"2014","unstructured":"Yoo HY, Sung MK, Lee SH, Kim S, Lee H, Park S, et al. A recurrent inactivating mutation in RHOA GTPase in angioimmunoblastic T cell lymphoma. Nat Genet. 2014;46:371\u20135.","journal-title":"Nat Genet"},{"key":"990_CR36","doi-asserted-by":"publisher","first-page":"e505","DOI":"10.3324\/haematol.2015.133074","volume":"100","author":"SH Lee","year":"2015","unstructured":"Lee SH, Kim JS, Kim J, Kim SJ, Kim WS, Lee S, et al. A highly recurrent novel missense mutation in CD28 among angioimmunoblastic T-cell lymphoma patients. Haematologica. 2015;100:e505\u20137.","journal-title":"Haematologica"},{"key":"990_CR37","doi-asserted-by":"publisher","first-page":"e148","DOI":"10.3324\/haematol.2016.158428","volume":"102","author":"MP Dobay","year":"2017","unstructured":"Dobay MP, Lemonnier F, Missiaglia E, Bastard C, Vallois D, Jais JP, et al. Integrative clinicopathological and molecular analyses of angioimmunoblastic T-cell lymphoma and other nodal lymphomas of follicular helper T-cell origin. Haematologica. 2017;102:e148\u201351.","journal-title":"Haematologica"},{"key":"990_CR38","doi-asserted-by":"publisher","first-page":"2867","DOI":"10.1038\/s41375-019-0473-1","volume":"33","author":"Y Watatani","year":"2019","unstructured":"Watatani Y, Sato Y, Miyoshi H, Sakamoto K, Nishida K, Gion Y, et al. Molecular heterogeneity in peripheral T-cell lymphoma, not otherwise specified revealed by comprehensive genetic profiling. Leukemia. 2019;33:2867\u201383.","journal-title":"Leukemia"},{"key":"990_CR39","doi-asserted-by":"publisher","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","volume":"26","author":"JM Vose","year":"2008","unstructured":"Vose JM, Armitage J, Weisenburger D. International peripheral T-cell and natural killer\/T-cell lymphoma study: Pathology findings and clinical outcomes international T-cell lymphoma project. J Clin Oncol. 2008;26:4124\u201330.","journal-title":"J Clin Oncol"},{"key":"990_CR40","doi-asserted-by":"publisher","first-page":"e361","DOI":"10.3324\/haematol.2015.126300","volume":"100","author":"L de Leval","year":"2015","unstructured":"de Leval L, Parrens M, Le Bras F, Jais J-P, Fataccioli V, Martin A, et al. Angioimmunoblastic T-cell lymphoma is the most common T-cell lymphoma in two distinct French information data sets. Haematologica. 2015;100:e361\u20134.","journal-title":"Haematologica"},{"key":"990_CR41","doi-asserted-by":"publisher","first-page":"4463","DOI":"10.1182\/blood-2007-08-105759","volume":"111","author":"N Mourad","year":"2008","unstructured":"Mourad N, Mounier N, Bri\u00e8re J, Raffoux E, Delmer A, Feller A, et al. Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the groupe d\u2019etude des lymphomes de i\u2019adulte (GELA) trials. Blood. 2008;111:4463\u201370.","journal-title":"Blood"},{"key":"990_CR42","doi-asserted-by":"publisher","first-page":"2837","DOI":"10.1182\/blood-2011-08-374371","volume":"119","author":"T Tokunaga","year":"2012","unstructured":"Tokunaga T, Shimada K, Yamamoto K, Chihara D, Ichihashi T, Oshima R, et al. Retrospective analysis of prognostic factors for angioimmunoblastic T-cell lymphoma: a multicenter cooperative study in Japan. Blood. 2012;119:2837\u201343.","journal-title":"Blood"},{"key":"990_CR43","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1200\/JCO.2011.37.3647","volume":"31","author":"M Federico","year":"2013","unstructured":"Federico M, Rudiger T, Bellei M, Nathwani BN, Luminari S, Coiffier B, et al. Clinicopathologic characteristics of angioimmunoblastic t-cell lymphoma: Analysis of the international peripheral t-cell lymphoma project. J Clin Oncol. 2013;31:240\u20136.","journal-title":"J Clin Oncol"},{"key":"990_CR44","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.3324\/haematol.2011.061507","volume":"97","author":"MH Delfau-Larue","year":"2012","unstructured":"Delfau-Larue MH, de Leval L, Joly B, Plonquet A, Challine D, Parrens M, et al. Targeting intratumoral B cells with rituximab in addition to CHOP in angioimmunoblastic T-cell lymphoma. A clinicobiological study of the GELA. Haematologica. 2012;97:1594\u2013602.","journal-title":"Haematologica"},{"key":"990_CR45","doi-asserted-by":"publisher","first-page":"2915","DOI":"10.1182\/blood-2013-11-536359","volume":"123","author":"J Iqbal","year":"2014","unstructured":"Iqbal J, Wright G, Wang C, Rosenwald A, Gascoyne RD, Weisenburger DD, et al. Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma. Blood. 2014;123:2915\u201323.","journal-title":"Blood"},{"key":"990_CR46","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1002\/cncr.31861","volume":"125","author":"SI Park","year":"2019","unstructured":"Park SI, Horwitz SM, Foss FM, Pinter-Brown LC, Carson KR, Rosen ST, et al. The role of autologous stem cell transplantation in patients with nodal peripheral T-cell lymphomas in first complete remission: report from COMPLETE, a prospective, multicenter cohort study. Cancer. 2019;125:1507\u201317.","journal-title":"Cancer"},{"key":"990_CR47","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.pathol.2019.09.012","volume":"52","author":"L de Leval","year":"2020","unstructured":"de Leval L. Approach to nodal-based T-cell lymphomas. Pathology. 2020;52:78\u201399.","journal-title":"Pathology"},{"key":"990_CR48","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1309\/28YP0DELGKEJGRXG","volume":"126","author":"SH Merchant","year":"2006","unstructured":"Merchant SH, Amin MB, Viswanatha DS. Morphologic and immunophenotypic analysis of angioimmunoblastic T-cell lymphoma: emphasis on phenotypic aberrancies for early diagnosis. Am J Clin Pathol. 2006;126:29\u201338.","journal-title":"Am J Clin Pathol"},{"key":"990_CR49","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.clml.2016.10.001","volume":"17","author":"ED Hsi","year":"2017","unstructured":"Hsi ED, Horwitz SM, Carson KR, Pinter-Brown LC, Rosen ST, Pro B, et al. Analysis of Peripheral T-cell Lymphoma Diagnostic Workup in the United States. Clin Lymphoma Myeloma Leuk. 2017;17:193\u2013200.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"990_CR50","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1111\/j.1365-2141.2009.08003.x","volume":"148","author":"L De Leval","year":"2010","unstructured":"De Leval L, Gisselbrecht C, Gaulard P. Advances in the understanding and management of angioimmunoblastic T-cell lymphoma. Br J Haematol. 2010;148:673\u201389.","journal-title":"Br J Haematol"},{"key":"990_CR51","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1111\/j.1440-1827.2007.02195.x","volume":"58","author":"K Karube","year":"2008","unstructured":"Karube K, Aoki R, Nomura Y, Yamamoto K, Shimizu K, Yoshida S, et al. Usefulness of flow cytometry for differential diagnosis of precursor and peripheral T-cell and NK-cell lymphomas: analysis of 490 cases. Pathol Int. 2008;58:89\u201397.","journal-title":"Pathol Int"},{"key":"990_CR52","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1002\/hon.2080","volume":"32","author":"A Singh","year":"2014","unstructured":"Singh A, Schabath R, Ratei R, Stroux A, Klemke C-D, Nebe T, et al. Peripheral blood sCD3(\u2212) CD4(+) T cells: a useful diagnostic tool in angioimmunoblastic T cell lymphoma. Hematol Oncol. 2014;32:16\u201321.","journal-title":"Hematol Oncol"},{"key":"990_CR53","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/S0046-8177(99)90115-6","volume":"30","author":"HJ Ree","year":"1999","unstructured":"Ree HJ, Kadin ME, Kikuchi M, Ko YH, Suzumiya J, Go JH. Bcl-6 expression in reactive follicular hyperplasia, follicular lymphoma, and angioimmunoblastic T-cell lymphoma with hyperplastic germinal centers: heterogeneity of intrafollicular T-cells and their altered distribution in the pathogenesis of angioimmuno. Hum Pathol. 1999;30:403\u201311.","journal-title":"Hum Pathol"},{"key":"990_CR54","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1182\/blood-2015-02-625152","volume":"125","author":"P Am\u00e9-Thomas","year":"2015","unstructured":"Am\u00e9-Thomas P, Hoeller S, Artchounin C, Misiak J, Braza MS, Jean R, et al. CD10 delineates a subset of human IL-4 producing follicular helper T cells involved in the survival of follicular lymphoma B cells. Blood. 2015;125:2381\u20135.","journal-title":"Blood"},{"key":"990_CR55","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1126\/science.1176676","volume":"325","author":"RI Nurieva","year":"2009","unstructured":"Nurieva RI, Chung Y, Martinez GJ, Yang XO, Tanaka S, Matskevitch TD, et al. Bcl6 mediates the development of T follicular helper cells. Science. 2009;325:1001\u20136.","journal-title":"Science"},{"key":"990_CR56","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1126\/science.1175870","volume":"325","author":"RJ Johnston","year":"2009","unstructured":"Johnston RJ, Poholek AC, DiToro D, Yusuf I, Eto D, Barnett B, et al. Bcl6 and Blimp-1 are reciprocal and antagonistic regulators of T follicular helper cell differentiation. Science. 2009;325:1006\u201310.","journal-title":"Science"},{"key":"990_CR57","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.immuni.2009.07.002","volume":"31","author":"D Yu","year":"2009","unstructured":"Yu D, Rao S, Tsai LM, Lee SK, He Y, Sutcliffe EL, et al. The transcriptional repressor Bcl-6 directs T follicular helper cell lineage commitment. Immunity. 2009;31:457\u201368.","journal-title":"Immunity"},{"key":"990_CR58","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1016\/j.immuni.2011.03.023","volume":"34","author":"YS Choi","year":"2011","unstructured":"Choi YS, Kageyama R, Eto D, Escobar TC, Johnston RJ, Monticelli L, et al. ICOS receptor instructs T follicular helper cell versus effector cell differentiation via induction of the transcriptional repressor Bcl6. Immunity. 2011;34:932\u201346.","journal-title":"Immunity"},{"key":"990_CR59","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.immuni.2018.06.012","volume":"49","author":"J Shi","year":"2018","unstructured":"Shi J, Hou S, Fang Q, Liu X, Liu X, Qi H. PD-1 controls follicular T helper cell positioning and function. Immunity. 2018;49:264\u201374.e4.","journal-title":"Immunity"},{"key":"990_CR60","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/nrm3589","volume":"14","author":"WA Pastor","year":"2013","unstructured":"Pastor WA, Aravind L, Rao A. TETonic shift: biological roles of TET proteins in DNA demethylation and transcription. Nat Rev Mol Cell Biol. 2013;14:341\u201356.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"990_CR61","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1038\/nrc3343","volume":"12","author":"AH Shih","year":"2012","unstructured":"Shih AH, Abdel-Wahab O, Patel JP, Levine RL. The role of mutations in epigenetic regulators in myeloid malignancies. Nat Rev Cancer. 2012;12:599\u2013612.","journal-title":"Nat Rev Cancer"},{"key":"990_CR62","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ccr.2011.06.001","volume":"20","author":"K Moran-Crusio","year":"2011","unstructured":"Moran-Crusio K, Reavie L, Shih A, Abdel-Wahab O, Ndiaye-Lobry D, Lobry C, et al. Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. Cancer Cell. 2011;20:11\u201324.","journal-title":"Cancer Cell"},{"key":"990_CR63","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2014.83","volume":"4","author":"H Muto","year":"2014","unstructured":"Muto H, Sakata-Yanagimoto M, Nagae G, Shiozawa Y, Miyake Y, Yoshida K, et al. Reduced TET2 function leads to T-cell lymphoma with follicular helper T-cell-like features in mice. Blood Cancer J. 2014;4:e264.","journal-title":"Blood Cancer J"},{"key":"990_CR64","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1182\/blood-2015-06-644948","volume":"127","author":"Y Nagata","year":"2016","unstructured":"Nagata Y, Kontani K, Enami T, Kataoka K, Ishii R, Totoki Y, et al. Variegated RHOA mutations in adult T-cell leukemia\/lymphoma. Blood. 2016;127:596\u2013604.","journal-title":"Blood"},{"key":"990_CR65","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1002\/gcc.22202","volume":"53","author":"M Rohde","year":"2014","unstructured":"Rohde M, Richter J, Schlesner M, Betts MJ, Claviez A, Bonn BR, et al. Recurrent RHOA mutations in pediatric Burkitt lymphoma treated according to the NHL-BFM protocols. Genes Chromosomes Cancer. 2014;53:911\u20136.","journal-title":"Genes Chromosomes Cancer"},{"key":"990_CR66","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/ng.2984","volume":"46","author":"M Kakiuchi","year":"2014","unstructured":"Kakiuchi M, Nishizawa T, Ueda H, Gotoh K, Tanaka A, Hayashi A, et al. Recurrent gain-of-function mutations of RHOA in diffuse-type gastric carcinoma. Nat Genet. 2014;46:583\u20137.","journal-title":"Nat Genet"},{"key":"990_CR67","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/bcj.2016.122","volume":"7","author":"TB Nguyen","year":"2017","unstructured":"Nguyen TB, Sakata-Yanagimoto M, Asabe Y, Matsubara D, Kano J, Yoshida K, et al. Identification of cell-type-specific mutations in nodal T-cell lymphomas. Blood Cancer J. 2017;7:1\u201310.","journal-title":"Blood Cancer J"},{"key":"990_CR68","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1038\/leu.2017.273","volume":"32","author":"M Fujisawa","year":"2018","unstructured":"Fujisawa M, Sakata-Yanagimoto M, Nishizawa S, Komori D, Gershon P, Kiryu M, et al. Activation of RHOA-VAV1 signaling in angioimmunoblastic T-cell lymphoma. Leukemia. 2018;32:694\u2013702.","journal-title":"Leukemia"},{"key":"990_CR69","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.coi.2005.04.003","volume":"17","author":"VLJ Tybulewicz","year":"2005","unstructured":"Tybulewicz VLJ. Vav-family proteins in T-cell signalling. Curr Opin Immunol. 2005;17:267\u201374.","journal-title":"Curr Opin Immunol"},{"key":"990_CR70","doi-asserted-by":"publisher","first-page":"ra83","DOI":"10.1126\/scisignal.2000420","volume":"2","author":"A Saveliev","year":"2009","unstructured":"Saveliev A, Vanes L, Ksionda O, Rapley J, Smerdon SJ, Rittinger K, et al. Function of the nucleotide exchange activity of vav1 in T cell development and activation. Sci Signal. 2009;2:ra83.","journal-title":"Sci Signal"},{"key":"990_CR71","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1128\/MCB.17.3.1346","volume":"17","author":"J Han","year":"1997","unstructured":"Han J, Das B, Wei W, Van Aelst L, Mosteller RD, Khosravi-Far R, et al. Lck regulates Vav activation of members of the Rho family of GTPases. Mol Cell Biol. 1997;17:1346\u201353.","journal-title":"Mol Cell Biol"},{"key":"990_CR72","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.cellsig.2003.09.013","volume":"16","author":"V Bertagnolo","year":"2004","unstructured":"Bertagnolo V, Brugnoli F, Marchisio M, Celeghini C, Carini C, Capitani S. Association of PI 3-K with tyrosine phosphorylated Vav is essential for its activity in neutrophil-like maturation of myeloid cells. Cell Signal. 2004;16:423\u201333.","journal-title":"Cell Signal"},{"key":"990_CR73","doi-asserted-by":"publisher","first-page":"10923","DOI":"10.1073\/pnas.97.20.10923","volume":"97","author":"J Huang","year":"2000","unstructured":"Huang J, Tilly D, Altman A, Sugie K, Grey HM. T-cell receptor antagonists induce Vav phosphorylation by selective activation of Fyn kinase. Proc Natl Acad Sci USA. 2000;97:10923\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"key":"990_CR74","doi-asserted-by":"publisher","first-page":"15257","DOI":"10.1021\/bi051126h","volume":"44","author":"GK Amarasinghe","year":"2005","unstructured":"Amarasinghe GK, Rosen MK. Acidic region tyrosines provide access points for allosteric activation of the autoinhibited Vav1 Db1 homology domain. Biochemistry. 2005;44:15257\u201368.","journal-title":"Biochemistry"},{"key":"990_CR75","doi-asserted-by":"publisher","first-page":"eaao2933","DOI":"10.1126\/science.aao2933","volume":"361","author":"D Ditoro","year":"2018","unstructured":"Ditoro D, Winstead C, Pham D, Witte S, Andargachew R, Singer JR, et al. Differential IL-2 expression defines developmental fates of follicular versus nonfollicular helper T cells. Science. 2018;361:eaao2933.","journal-title":"Science"},{"key":"990_CR76","doi-asserted-by":"publisher","first-page":"2998","DOI":"10.1172\/JCI92026","volume":"127","author":"S Zang","year":"2017","unstructured":"Zang S, Li J, Yang H, Zeng H, Han W, Zhang J, et al. Mutations in 5-methylcytosine oxidase TET2 and RhoA cooperatively disrupt T cell homeostasis. J Clin Investig. 2017;127:2998\u20133012.","journal-title":"J Clin Investig"},{"key":"990_CR77","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.ccell.2018.01.001","volume":"33","author":"JR Cortes","year":"2018","unstructured":"Cortes JR, Ambesi-Impiombato A, Couronn\u00e9 L, Quinn SA, Kim CS, da Silva Almeida AC, et al. RHOA G17V induces T follicular helper cell specification and promotes lymphomagenesis. Cancer Cell. 2018;33:259\u201373.e7.","journal-title":"Cancer Cell"},{"key":"990_CR78","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1182\/blood-2017-11-818617","volume":"132","author":"SY Ng","year":"2018","unstructured":"Ng SY, Brown L, Stevenson K, DeSouza T, Aster JC, Louissaint A, et al. RhoA G17V is sufficient to induce autoimmunity and promotes T-cell lymphomagenesis in mice. Blood. 2018;132:935\u201347.","journal-title":"Blood"},{"key":"990_CR79","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.immuni.2015.01.017","volume":"42","author":"EL Stone","year":"2015","unstructured":"Stone EL, Pepper M, Katayama CD, Kerdiles YM, Lai CY, Emslie E, et al. ICOS coreceptor signaling inactivates the transcription factor FOXO1 to promote Tfh cell differentiation. Immunity. 2015;42:239\u201351.","journal-title":"Immunity"},{"key":"990_CR80","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1084\/jem.20141432","volume":"212","author":"JP Weber","year":"2015","unstructured":"Weber JP, Fuhrmann F, Feist RK, Lahmann A, Al Baz MS, Gentz LJ, et al. ICOS maintains the T follicular helper cell phenotype by down-regulating kr\u00fcppel-like factor 2. J Exp Med. 2015;212:217\u201333.","journal-title":"J Exp Med"},{"key":"990_CR81","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1158\/0008-5472.CAN-19-2787","volume":"80","author":"TB Nguyen","year":"2020","unstructured":"Nguyen TB, Sakata-Yanagimoto M, Fujisawa M, Nuhat ST, Miyoshi H, Nannya Y, et al. Dasatinib is an effective treatment for angioimmunoblastic T-cell lymphoma. Cancer Res. 2020;80:1875\u201384.","journal-title":"Cancer Res"},{"key":"990_CR82","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1158\/2159-8290.CD-18-0657","volume":"8","author":"PM Dominguez","year":"2018","unstructured":"Dominguez PM, Ghamlouch H, Rosikiewicz W, Kumar P, B\u00e9guelin W, Font\u00e1n L, et al. TET2 deficiency causes germinal center hyperplasia, impairs plasma cell differentiation, and promotes b-cell lymphomagenesis. Cancer Discov. 2018;8:1633\u201353.","journal-title":"Cancer Discov"},{"key":"990_CR83","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.ccr.2010.01.020","volume":"17","author":"PS Ward","year":"2010","unstructured":"Ward PS, Patel J, Wise DR, Abdel-Wahab O, Bennett BD, Coller HA, et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting \u03b1-ketoglutarate to 2-hydroxyglutarate. Cancer Cell. 2010;17:225\u201334.","journal-title":"Cancer Cell"},{"key":"990_CR84","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/nature08617","volume":"462","author":"L Dang","year":"2009","unstructured":"Dang L, White DW, Gross S, Bennett BD, Bittinger MA, Driggers EM, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature. 2009;462:739\u201344.","journal-title":"Nature"},{"key":"990_CR85","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1038\/nature10860","volume":"483","author":"C Lu","year":"2012","unstructured":"Lu C, Ward PS, Kapoor GS, Rohle D, Turcan S, Abdel-Wahab O, et al. IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature. 2012;483:474\u20138.","journal-title":"Nature"},{"key":"990_CR86","doi-asserted-by":"publisher","first-page":"15084","DOI":"10.1073\/pnas.1617929114","volume":"113","author":"F Lemonnier","year":"2016","unstructured":"Lemonnier F, Cairns RA, Inoue S, Li WY, Dupuy A, Broutin S, et al. The IDH2 R172K mutation associated with angioimmunoblastic T-cell lymphoma produces 2HG in T cells and impacts lymphoid development. Proc Natl Acad Sci USA. 2016;113:15084\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"key":"990_CR87","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1182\/blood-2016-03-707141","volume":"128","author":"RL Boddicker","year":"2016","unstructured":"Boddicker RL, Razidlo GL, Dasari S, Zeng Y, Hu G, Knudson RA, et al. Integrated mate-pair and RNA sequencing identifies novel, targetable gene fusions in peripheral T-cell lymphoma. Blood. 2016;128:1234\u201345.","journal-title":"Blood"},{"key":"990_CR88","doi-asserted-by":"publisher","first-page":"757","DOI":"10.3324\/haematol.2015.139253","volume":"101","author":"HY Yoo","year":"2016","unstructured":"Yoo HY, Kim P, Kim WS, Lee SH, Kim S, Kang SY, et al. Frequent CTLA4-CD28 gene fusion in diverse types of T-cell lymphoma. Haematologica. 2016;101:757\u201363.","journal-title":"Haematologica"},{"key":"990_CR89","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1038\/ng.3415","volume":"47","author":"K Kataoka","year":"2015","unstructured":"Kataoka K, Nagata Y, Kitanaka A, Shiraishi Y, Shimamura T, Yasunaga JI, et al. Integrated molecular analysis of adult T cell leukemia\/lymphoma. Nat Genet. 2015;47:1304\u201315.","journal-title":"Nat Genet"},{"key":"990_CR90","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1038\/ng.3610","volume":"48","author":"X Zhang","year":"2016","unstructured":"Zhang X, Su J, Jeong M, Ko M, Huang Y, Park HJ, et al. DNMT3A and TET2 compete and cooperate to repress lineage-specific transcription factors in hematopoietic stem cells. Nat Genet. 2016;48:1014\u201323.","journal-title":"Nat Genet"},{"key":"990_CR91","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1038\/leu.2016.29","volume":"30","author":"L Scourzic","year":"2016","unstructured":"Scourzic L, Couronne L, Pedersen MT, Della Valle V, Diop M, Mylonas E, et al. DNMT3A(R882H) mutant and Tet2 inactivation cooperate in the deregulation of DNA methylation control to induce lymphoid malignancies in mice. Leukemia. 2016;30:1388\u201398.","journal-title":"Leukemia"},{"key":"990_CR92","doi-asserted-by":"publisher","first-page":"e64536","DOI":"10.1371\/journal.pone.0064536","volume":"8","author":"T Auguste","year":"2013","unstructured":"Auguste T, Travert M, Tarte K, Ame-Thomas P, Artchounin C, Martin-Garcia N, et al. ROQUIN\/RC3H1 alterations are not found in angioimmunoblastic T-cell lymphoma. PLoS ONE. 2013;8:e64536.","journal-title":"PLoS ONE"},{"key":"990_CR93","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1182\/blood-2011-07-365130","volume":"120","author":"JI Ellyard","year":"2012","unstructured":"Ellyard JI, Chia T, Rodriguez-Pinilla S-M, Martin JL, Hu X, Navarro-Gonzalez M, et al. Heterozygosity for Roquinsan leads to angioimmunoblastic T-cell lymphoma-like tumors in mice. Blood. 2012;120:812\u201321.","journal-title":"Blood"},{"key":"990_CR94","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/nature03555","volume":"435","author":"CG Vinuesa","year":"2005","unstructured":"Vinuesa CG, Cook MC, Angelucci C, Athanasopoulos V, Rui L, Hill KM, et al. A RING-type ubiquitin ligase family member required to repress follicular helper T cells and autoimmunity. Nature. 2005;435:452\u20138.","journal-title":"Nature"},{"key":"990_CR95","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/nature06253","volume":"450","author":"YU Di","year":"2007","unstructured":"Di YU, Tan AHM, Hu X, Athanasopoulos V, Simpson N, Silva DG, et al. Roquin represses autoimmunity by limiting inducible T-cell co-stimulator messenger RNA. Nature. 2007;450:299\u2013303.","journal-title":"Nature"},{"key":"990_CR96","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/j.cell.2007.03.045","volume":"129","author":"A Colell","year":"2007","unstructured":"Colell A, Ricci JE, Tait S, Milasta S, Maurer U, Bouchier-Hayes L, et al. GAPDH and autophagy preserve survival after apoptotic cytochrome c release in the absence of caspase activation. Cell. 2007;129:983\u201397.","journal-title":"Cell"},{"key":"990_CR97","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1038\/cdd.2013.32","volume":"20","author":"MA Jacquin","year":"2013","unstructured":"Jacquin MA, Chiche J, Zunino B, B\u00e9n\u00e9teau M, Meynet O, Pradelli LA, et al. GAPDH binds to active Akt, leading to Bcl-xL increase and escape from caspase-independent cell death. Cell Death Differ. 2013;20:1043\u201354.","journal-title":"Cell Death Differ"},{"key":"990_CR98","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.ccell.2019.07.008","volume":"36","author":"L Mondrag\u00f3n","year":"2019","unstructured":"Mondrag\u00f3n L, Mhaidly R, De Donatis GM, Tosolini M, Dao P, Martin AR, et al. GAPDH overexpression in the T cell lineage promotes angioimmunoblastic T cell lymphoma through an NF-\u03baB-dependent mechanism. Cancer Cell. 2019;36:268\u201387.e10.","journal-title":"Cancer Cell"},{"key":"990_CR99","doi-asserted-by":"publisher","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","volume":"371","author":"S Jaiswal","year":"2014","unstructured":"Jaiswal S, Fontanillas P, Flannick J, Manning A, Grauman PV, Mar BG, et al. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med. 2014;371:2488\u201398.","journal-title":"N Engl J Med"},{"key":"990_CR100","doi-asserted-by":"publisher","first-page":"2477","DOI":"10.1056\/NEJMoa1409405","volume":"371","author":"G Genovese","year":"2014","unstructured":"Genovese G, K\u00e4hler AK, Handsaker RE, Lindberg J, Rose SA, Bakhoum SF, et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med. 2014;371:2477\u201387.","journal-title":"N Engl J Med"},{"key":"990_CR101","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/ng.1009","volume":"44","author":"GA Challen","year":"2012","unstructured":"Challen GA, Sun D, Jeong M, Luo M, Jelinek J, Berg JS, et al. Dnmt3a is essential for hematopoietic stem cell differentiation. Nat Genet. 2012;44:23\u201331.","journal-title":"Nat Genet"},{"key":"990_CR102","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1002\/path.4898","volume":"242","author":"FH Schwartz","year":"2017","unstructured":"Schwartz FH, Cai Q, Fellmann E, Hartmann S, M\u00e4yr\u00e4np\u00e4\u00e4 MI, Karjalainen-Lindsberg ML, et al. TET2 mutations in B cells of patients affected by angioimmunoblastic T-cell lymphoma. J Pathol. 2017;242:129\u201333.","journal-title":"J Pathol"},{"key":"990_CR103","first-page":"416","volume":"4","author":"AN Ahsanuddin","year":"2011","unstructured":"Ahsanuddin AN, Brynes RK, Li S. Peripheral blood polyclonal plasmacytosis mimicking plasma cell leukemia in patients with angioimmunoblastic T-cell lymphoma: report of 3 cases and review of the literature. Int J Clin Exp Pathol. 2011;4:416\u201320.","journal-title":"Int J Clin Exp Pathol"},{"key":"990_CR104","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1007\/s12185-013-1411-z","volume":"98","author":"H Nagoshi","year":"2013","unstructured":"Nagoshi H, Kuroda J, Kobayashi T, Maegawa S, Chinen Y, Kiyota M, et al. Clinical manifestation of angioimmunoblastic T-cell lymphoma with exuberant plasmacytosis. Int J Hematol. 2013;98:366\u201374.","journal-title":"Int J Hematol"},{"key":"990_CR105","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/nature15252","volume":"525","author":"Q Zhang","year":"2015","unstructured":"Zhang Q, Zhao K, Shen Q, Han Y, Gu Y, Li X, et al. Tet2 is required to resolve inflammation by recruiting Hdac2 to specifically repress IL-6. Nature. 2015;525:389\u201393.","journal-title":"Nature"},{"key":"990_CR106","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1056\/NEJMoa1701719","volume":"377","author":"S Jaiswal","year":"2017","unstructured":"Jaiswal S, Natarajan P, Silver AJ, Gibson CJ, Bick AG, Shvartz E, et al. Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease. N Engl J Med. 2017;377:111\u201321.","journal-title":"N Engl J Med"},{"key":"990_CR107","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1002\/path.5376","volume":"250","author":"WQ Yao","year":"2020","unstructured":"Yao WQ, Wu F, Zhang W, Chuang SS, Thompson JS, Chen Z, et al. Angioimmunoblastic T-cell lymphoma contains multiple clonal T-cell populations derived from a common TET2 mutant progenitor cell. J Pathol. 2020;250:346\u201357.","journal-title":"J Pathol"},{"key":"990_CR108","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1084\/jem.194.7.927","volume":"194","author":"A Br\u00e4uninger","year":"2001","unstructured":"Br\u00e4uninger A, Spieker T, Willenbrock K, Gaulard P, Wacker HH, Rajewsky K, et al. Survival and clonal expansion of mutating \u2018forbidden\u2019 (immunoglobulin receptor-deficient) Epstein\u2013Barr virus-infected B cells in angioimmunoblastic T cell lymphoma. J Exp Med. 2001;194:927\u201340.","journal-title":"J Exp Med"},{"key":"990_CR109","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1097\/PAS.0b013e3182785610","volume":"37","author":"A Nicolae","year":"2013","unstructured":"Nicolae A, Pittaluga S, Venkataraman G, Vijnovich-Baron A, Xi L, Raffeld M, et al. Peripheral T-cell lymphomas of follicular T-helper cell derivation with Hodgkin\/Reed\u2013Sternberg cells of B-cell lineage: both EBV- positive and EBV-negative variants exist. Am J Surg Pathol. 2013;37:816\u201326.","journal-title":"Am J Surg Pathol"},{"key":"990_CR110","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1111\/j.1440-1827.2012.02858.x","volume":"62","author":"N Suefuji","year":"2012","unstructured":"Suefuji N, Niino D, Arakawa F, Karube K, Kimura Y, Kiyasu J, et al. Clinicopathological analysis of a composite lymphoma containing both T- and B-cell lymphomas. Pathol Int. 2012;62:690\u20138.","journal-title":"Pathol Int"},{"key":"990_CR111","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1038\/s41375-019-0380-5","volume":"33","author":"K Kataoka","year":"2019","unstructured":"Kataoka K, Miyoshi H, Sakata S, Dobashi A, Couronn\u00e9 L, Kogure Y, et al. Frequent structural variations involving programmed death ligands in Epstein\u2013Barr virus-associated lymphomas. Leukemia. 2019;33:1687\u201399.","journal-title":"Leukemia"},{"key":"990_CR112","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1111\/j.1365-2141.2007.06725.x","volume":"138","author":"K Willenbrock","year":"2007","unstructured":"Willenbrock K, Br\u00e4uninger A, Hansmann M-L. Frequent occurrence of B-cell lymphomas in angioimmunoblastic T-cell lymphoma and proliferation of Epstein\u2013Barr virus-infected cells in early cases. Br J Haematol. 2007;138:733\u20139.","journal-title":"Br J Haematol"},{"key":"990_CR113","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/nrc.2016.8","volume":"16","author":"G Fabbri","year":"2016","unstructured":"Fabbri G, Dalla-Favera R. The molecular pathogenesis of chronic lymphocytic leukaemia. Nat Rev Cancer. 2016;16:145\u201362.","journal-title":"Nat Rev Cancer"},{"key":"990_CR114","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1182\/blood-2011-11-391474","volume":"119","author":"R Kridel","year":"2012","unstructured":"Kridel R, Meissner B, Rogic S, Boyle M, Telenius A, Woolcock B, et al. Whole transcriptome sequencing reveals recurrent NOTCH1 mutations in mantle cell lymphoma. Blood. 2012;119:1963\u201371.","journal-title":"Blood"},{"key":"990_CR115","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1056\/NEJMoa1801445","volume":"378","author":"R Schmitz","year":"2018","unstructured":"Schmitz R, Wright GW, Huang DW, Johnson CA, Phelan JD, Wang JQ, et al. Genetics and pathogenesis of diffuse large B-Cell lymphoma. N Engl J Med. 2018;378:1396\u2013407.","journal-title":"N Engl J Med"},{"key":"990_CR116","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1016\/j.celrep.2017.09.066","volume":"21","author":"RJH Ryan","year":"2017","unstructured":"Ryan RJH, Petrovic J, Rausch DM, Zhou Y, Lareau CA, Kluk MJ, et al. A B cell regulome links notch to downstream oncogenic pathways in small B cell lymphomas. Cell Rep. 2017;21:784\u201397.","journal-title":"Cell Rep"},{"key":"990_CR117","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.semcancer.2013.11.004","volume":"24","author":"P Gaulard","year":"2014","unstructured":"Gaulard P, de Leval L. The microenvironment in T-cell lymphomas: emerging themes. Semin Cancer Biol. 2014;24:49\u201360.","journal-title":"Semin Cancer Biol"},{"key":"990_CR118","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.immuni.2007.07.009","volume":"27","author":"CDC Allen","year":"2007","unstructured":"Allen CDC, Okada T, Cyster JG. Germinal-center organization and cellular dynamics. Immunity. 2007;27:190\u2013202.","journal-title":"Immunity"},{"key":"990_CR119","first-page":"1635","volume":"50","author":"K Nanba","year":"1987","unstructured":"Nanba K, Sasaki N. Pathology of diffuse lesion of the lymph node with cellular atypism-a proposal for diffuse lymphoid dysplasia or lymphodysplastic syndrome. Nihon Ketsueki Gakkai Zasshi. 1987;50:1635\u201343.","journal-title":"Nihon Ketsueki Gakkai Zasshi"},{"key":"990_CR120","doi-asserted-by":"crossref","unstructured":"Bennani NN, Pederson LD, Atherton P, Micallef I, Colgan JP, Thanarajasingam G, et al. A phase II study of nivolmab in patients with relapsed or regractory peripheral T-cell lymphoma. Blood. 2019;134 (supplement_1):467.","DOI":"10.1182\/blood-2019-126194"},{"key":"990_CR121","unstructured":"Bennett C. Hyperprogression halts study of nivolman in peripheral T-cell lymphoma. Cancer Ther. Advis. 2019. https:\/\/www.cancertherapyadvisor.com\/home\/news\/conference-coverage\/american-society-of-hematology-ash\/ash-2019\/nivolumab-tcell-lymphoma-hyperprogression-halts-study\/. Accessed 17 Jun 2020."},{"key":"990_CR122","doi-asserted-by":"publisher","first-page":"43295","DOI":"10.18632\/oncotarget.17177","volume":"8","author":"Y Lin","year":"2017","unstructured":"Lin Y, Lin Z, Cheng K, Fang Z, Li Z, Luo Y, et al. Prognostic role of TET2 deficiency in myelodysplastic syndromes: a meta-analysis. Oncotarget. 2017;8:43295\u2013305.","journal-title":"Oncotarget"},{"key":"990_CR123","doi-asserted-by":"publisher","first-page":"106948","DOI":"10.18632\/oncotarget.22157","volume":"8","author":"MT Cedena","year":"2017","unstructured":"Cedena MT, Rapado I, Santos-Lozano A, Ayala R, Onecha E, Abaigar M, et al. Mutations in the DNA methylation pathway and number of driver mutations predict response to azacitidine in myelodysplastic syndromes. Oncotarget. 2017;8:106948\u201361.","journal-title":"Oncotarget"},{"key":"990_CR124","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1182\/blood-2018-04-840538","volume":"132","author":"F Lemonnier","year":"2018","unstructured":"Lemonnier F, Dupuis J, Sujobert P, Tournillhac O, Cheminant M, Sarkozy C, et al. Treatment with 5-azacytidine induces a sustained response in patients with angioimmunoblastic T-cell lymphoma. Blood. 2018;132:2305\u20139.","journal-title":"Blood"},{"key":"990_CR125","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1182\/blood.2019001285","volume":"134","author":"OA O\u2019Connor","year":"2019","unstructured":"O\u2019Connor OA, Falchi L, Lue JK, Marchi E, Kinahan C, Sawas A, et al. Oral 5-azacytidine and romidepsin exhibit marked activity in patients with PTCL: a multicenter phase 1 study. Blood. 2019;134:1395\u2013405.","journal-title":"Blood"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-020-0990-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-020-0990-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-020-0990-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,4]],"date-time":"2022-11-04T00:56:43Z","timestamp":1667523403000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-020-0990-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,23]]},"references-count":125,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["990"],"URL":"https:\/\/doi.org\/10.1038\/s41375-020-0990-y","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,23]]},"assertion":[{"value":"10 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors are conducting a phase II clinical trial of dasatinib in AITL and other Tfh lymphoma patients with a drug supply from Bristol-Meyer Squibb that sells dasatinib.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}